CN101128199B - 作为激酶抑制剂的单环杂环 - Google Patents

作为激酶抑制剂的单环杂环 Download PDF

Info

Publication number
CN101128199B
CN101128199B CN200580020112.2A CN200580020112A CN101128199B CN 101128199 B CN101128199 B CN 101128199B CN 200580020112 A CN200580020112 A CN 200580020112A CN 101128199 B CN101128199 B CN 101128199B
Authority
CN
China
Prior art keywords
fluorophenyl
amino
mixture
esi
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200580020112.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN101128199A (zh
Inventor
R·M·博尔齐莱里
L·A·M·科恩利乌斯
R·J·施米德特
G·M·施勒德尔
K·S·金
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/111,144 external-priority patent/US7459562B2/en
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN101128199A publication Critical patent/CN101128199A/zh
Application granted granted Critical
Publication of CN101128199B publication Critical patent/CN101128199B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN200580020112.2A 2004-04-23 2005-04-22 作为激酶抑制剂的单环杂环 Active CN101128199B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US56484204P 2004-04-23 2004-04-23
US60/564,842 2004-04-23
US63917804P 2004-12-23 2004-12-23
US60/639,178 2004-12-23
US11/111,144 US7459562B2 (en) 2004-04-23 2005-04-21 Monocyclic heterocycles as kinase inhibitors
US11/111,144 2005-04-21
PCT/US2005/014120 WO2005117867A2 (en) 2004-04-23 2005-04-22 Monocyclic heterocycles as kinase inhibitors

Publications (2)

Publication Number Publication Date
CN101128199A CN101128199A (zh) 2008-02-20
CN101128199B true CN101128199B (zh) 2013-07-24

Family

ID=39095986

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200580020112.2A Active CN101128199B (zh) 2004-04-23 2005-04-22 作为激酶抑制剂的单环杂环

Country Status (4)

Country Link
CN (1) CN101128199B (uk)
ES (1) ES2359836T3 (uk)
UA (1) UA85087C2 (uk)
ZA (1) ZA200608775B (uk)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011004535A (es) * 2008-10-29 2011-11-18 Deciphera Pharmaceuticals Llc Ciclopropanamidas y analogos que exhiben actividades anti-cancer y anti-proliferativas.
AR076332A1 (es) * 2009-04-21 2011-06-01 Boehringer Ingelheim Int Derivados heterociclicos de 5-alquinil-piridinas, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento y/o prevencion del cancer, procesos inflamatorios, autoinmunes, y/o infecciones.
CN102285914B (zh) * 2010-06-18 2013-12-25 上海药明康德新药开发有限公司 2-(1-甲基-6-羰基-1,6-二氢-吡啶)-乙酸的合成方法
CN102816175B (zh) * 2011-06-09 2015-12-16 上海汇伦生命科技有限公司 一种杂环并吡啶酮类化合物,其中间体、制备方法和用途
TWI570116B (zh) * 2012-08-03 2017-02-11 習寧 取代的吡唑酮化合物及其使用方法
CN102875455A (zh) * 2012-10-23 2013-01-16 西华大学 一种3,6-二氯-2-氨基吡啶的合成工艺
EP3013345B1 (en) * 2013-06-25 2017-11-22 F. Hoffmann-La Roche AG Compounds for treating spinal muscular atrophy
CN110520416B (zh) * 2017-10-26 2022-06-03 北京越之康泰生物医药科技有限公司 多取代吡啶酮类衍生物、其制备方法及其医药用途
KR20210066820A (ko) * 2018-08-27 2021-06-07 베이징 위에즈캉타이 바이오메디슨스 컴퍼니, 리미티드 다중-치환된 피리돈 유도체 및 이의 의학적 용도
CN113999205B (zh) * 2021-12-13 2023-09-15 辽宁大学 含三氮唑酮酰胺和咪唑酰胺结构的吡啶类化合物及其应用
CN117486860A (zh) * 2022-07-25 2024-02-02 上海博悦生物科技有限公司 Axl&c-Met双重抑制剂、制备方法以及用途
CN116870968B (zh) * 2023-09-08 2023-11-10 烟台大学 铱配合物功能化纳米石墨烯催化剂、其制备方法与应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1411046A1 (en) * 2001-06-22 2004-04-21 Kirin Beer Kabushiki Kaisha QUINOLINE DERIVATIVE AND QUINAZOLINE DERIVATIVE INHIBITING SELF−PHOSPHORYLATION OF HEPATOCYTUS PROLIFERATOR RECEPTOR, AND MEDICINAL COMPOSITION CONTAINING THE SAME
WO2005005389A2 (en) * 2003-07-07 2005-01-20 Merck Patent Gmbh Malonamide derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1411046A1 (en) * 2001-06-22 2004-04-21 Kirin Beer Kabushiki Kaisha QUINOLINE DERIVATIVE AND QUINAZOLINE DERIVATIVE INHIBITING SELF−PHOSPHORYLATION OF HEPATOCYTUS PROLIFERATOR RECEPTOR, AND MEDICINAL COMPOSITION CONTAINING THE SAME
WO2005005389A2 (en) * 2003-07-07 2005-01-20 Merck Patent Gmbh Malonamide derivatives

Also Published As

Publication number Publication date
ES2359836T3 (es) 2011-05-27
CN101128199A (zh) 2008-02-20
ZA200608775B (en) 2008-06-25
UA85087C2 (en) 2008-12-25

Similar Documents

Publication Publication Date Title
CN101128199B (zh) 作为激酶抑制剂的单环杂环
JP4778959B2 (ja) キナーゼ阻害剤としての単環式複素環
JP6959250B2 (ja) 癌治療用の２−シアノイソインドリン誘導体
WO2020135771A1 (zh) 杂环类化合物、中间体、其制备方法及应用
CN100577663C (zh) 稠合杂环型激酶抑制剂
TW202144345A (zh) Ｋｒａｓ突變蛋白抑制劑
JP4860609B2 (ja) 縮合ヘテロ環キナーゼ阻害剤
KR102057877B1 (ko) 질소함유 헤테로고리 유도체 및 그의 약물에서의 용도
CN113286794A (zh) Kras突变蛋白抑制剂
CA3093851A1 (en) Substituted 1,1'-biphenyl compounds, analogues thereof, and methods using same
KR20130001309A (ko) 피라졸-4-일-헤테로사이클릴-카복사마이드 화합물 및 사용 방법
CN104703987A (zh) 具有咪唑并吡嗪酮骨架的pde9抑制剂
CN111356695B (zh) 新的三环化合物
WO2020143763A1 (zh) 卤代烯丙基胺类化合物及其应用
CN104039766A (zh) 药物化合物
WO2022048631A1 (zh) 一种具有抗肿瘤活性的化合物及其用途
CN1880317B (zh) 作为细胞周期蛋白依赖性激酶抑制剂的吡唑并嘧啶
CN112513041A (zh) 三环化合物
WO2021147940A1 (zh) 一种pd-1/pd-l1抑制剂及其制备方法和用途
CN101321751A (zh) Met激酶抑制剂
CN101370812A (zh) 稠合的杂环化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant